219 related articles for article (PubMed ID: 22426030)
1. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.
Pulido J; Kottke T; Thompson J; Galivo F; Wongthida P; Diaz RM; Rommelfanger D; Ilett E; Pease L; Pandha H; Harrington K; Selby P; Melcher A; Vile R
Nat Biotechnol; 2012 Mar; 30(4):337-43. PubMed ID: 22426030
[TBL] [Abstract][Full Text] [Related]
2. The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.
Alonso-Camino V; Rajani K; Kottke T; Rommelfanger-Konkol D; Zaidi S; Thompson J; Pulido J; Ilett E; Donnelly O; Selby P; Pandha H; Melcher A; Harrington K; Diaz RM; Vile R
Mol Ther; 2014 Nov; 22(11):1936-48. PubMed ID: 25059678
[TBL] [Abstract][Full Text] [Related]
3. Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.
Zaidi S; Blanchard M; Shim K; Ilett E; Rajani K; Parrish C; Boisgerault N; Kottke T; Thompson J; Celis E; Pulido J; Selby P; Pandha H; Melcher A; Harrington K; Vile R
Mol Ther; 2015 May; 23(5):845-856. PubMed ID: 25544599
[TBL] [Abstract][Full Text] [Related]
4. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
[TBL] [Abstract][Full Text] [Related]
5. Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.
Boisgerault N; Kottke T; Pulido J; Thompson J; Diaz RM; Rommelfanger-Konkol D; Embry A; Saenz D; Poeschla E; Pandha H; Harrington K; Melcher A; Selby P; Vile R
Mol Ther; 2013 Aug; 21(8):1507-16. PubMed ID: 23752316
[TBL] [Abstract][Full Text] [Related]
6. Selecting antigens for cancer vaccines.
Avogadri F; Wolchok JD
Nat Biotechnol; 2012 Apr; 30(4):328-9. PubMed ID: 22491282
[No Abstract] [Full Text] [Related]
7. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
Kahn M; Sugawara H; McGowan P; Okuno K; Nagoya S; Hellström KE; Hellström I; Greenberg P
J Immunol; 1991 May; 146(9):3235-41. PubMed ID: 1707934
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
10. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.
Bridle BW; Boudreau JE; Lichty BD; Brunellière J; Stephenson K; Koshy S; Bramson JL; Wan Y
Mol Ther; 2009 Oct; 17(10):1814-21. PubMed ID: 19603003
[TBL] [Abstract][Full Text] [Related]
11. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
12. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
[TBL] [Abstract][Full Text] [Related]
13. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
[TBL] [Abstract][Full Text] [Related]
14. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules.
Chiari R; Hames G; Stroobant V; Texier C; Maillère B; Boon T; Coulie PG
Cancer Res; 2000 Sep; 60(17):4855-63. PubMed ID: 10987298
[TBL] [Abstract][Full Text] [Related]
15. Melanoma skin test antigens of improved sensitivity prepared from vesicular stomatitis virus-infected tumor cells.
Boone CW; Austin FC; Gail M; Case R; Klein E
Cancer; 1978 May; 41(5):1781-7. PubMed ID: 77181
[TBL] [Abstract][Full Text] [Related]
16. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
[TBL] [Abstract][Full Text] [Related]
17. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
18. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
Blanchard M; Shim KG; Grams MP; Rajani K; Diaz RM; Furutani KM; Thompson J; Olivier KR; Park SS; Markovic SN; Pandha H; Melcher A; Harrington K; Zaidi S; Vile R
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):577-87. PubMed ID: 26461000
[TBL] [Abstract][Full Text] [Related]
19. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.
Tsuji T; Matsuzaki J; Caballero OL; Jungbluth AA; Ritter G; Odunsi K; Old LJ; Gnjatic S
J Immunol; 2012 Apr; 188(8):3851-8. PubMed ID: 22427632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
